Related Experiment Video
Updated: Feb 27, 2026

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
Inducible nitric oxide synthase: Good or bad?
Maggie Lind1, Alan Hayes1, Martin Caprnda2
1Centre for Chronic Disease (CCD), College of Health & Biomedicine, Victoria University, Melbourne, Victoria, Australia.
Abstract:
Nitric oxide synthases (NOS) are a family of isoforms responsible for the synthesis of the potent dilator nitric oxide (NO). Expression of inducible NOS (iNOS) occurs in conditions of inflammation, and produces large amounts of NO. In pathological conditions iNOS is regarded as a harmful enzyme and is proposed to be a major contributor to diseases of the cardiovascular system such as atherosclerosis. In this review, we address the notion that iNOS is a detrimental enzyme in disease and discuss its potentially beneficial roles. Additionally, we describe other molecules associated with iNOS in diseases such as atherosclerosis, and current research on therapeutic inhibitors tested to reduced pathology associated with cardiovascular diseases (CVD).
Insights
Inducible nitric oxide synthase (iNOS) produces nitric oxide (NO) during inflammation. While often seen as harmful in cardiovascular diseases like atherosclerosis, this review explores its potentially beneficial roles and therapeutic inhibition strategies.
Area of Science:
- Biochemistry
- Cardiovascular Science
- Immunology
Background:
- Nitric oxide synthases (NOS) produce nitric oxide (NO), a key signaling molecule.
- Inducible NOS (iNOS) expression is upregulated during inflammation.
- iNOS is implicated in cardiovascular diseases, particularly atherosclerosis.
Purpose of the Study:
- To critically evaluate the detrimental role of iNOS in disease.
- To explore the potentially beneficial functions of iNOS.
- To review molecules associated with iNOS in atherosclerosis and therapeutic inhibition strategies for cardiovascular diseases (CVD).
Main Methods:
- Literature review of scientific articles on iNOS, NO, and cardiovascular diseases.
- Analysis of existing research on the dual role of iNOS in pathological conditions.
- Examination of therapeutic approaches targeting iNOS in CVD.
Main Results:
- iNOS is traditionally viewed as a detrimental enzyme in inflammatory conditions and CVD.
- Emerging evidence suggests iNOS may possess protective functions in certain contexts.
- Several therapeutic inhibitors targeting iNOS are under investigation for CVD treatment.
Conclusions:
- The role of iNOS in cardiovascular diseases is complex and context-dependent.
- Further research is needed to fully elucidate the beneficial and detrimental effects of iNOS.
- Targeting iNOS presents a potential therapeutic avenue for managing cardiovascular pathologies, but requires careful consideration of its dual nature.
More Related Videos
Related Concept Videos
Nitric Oxide Signaling Pathway
Antihypertensive Drugs: Vasodilators
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Paracrine Signaling
2° Amines to N-Nitrosamines: Reaction with NaNO2
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

